Debabrata Bandyopadhyay, MD
Critical Care Medicine · Tampa, FLNPI 1942431135
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $300,111 of the $397,794 with a category attached, or 75.4%. 21 manufacturers reported payments, led by United Therapeutics Corporation at 51.0% of the total. 2025 is the largest year on record at $97,316, more than ten times the $772 reported in 2019. Among critical care medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 485 payments — averaging $820.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$203K
- Boehringer Ingelheim$156K
- ANI Pharmaceuticals, Inc.$31K
- Actelion Pharmaceuticals US, Inc.$5K
- Genentech, Inc.$691
- Mallinckrodt Hospital Products Inc.$296
- plus $1K from 15 others
Across 288 payments — averaging $5303.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$814K
- Boehringer Ingelheim$389K
- E.r. Squibb & Sons, L.L.C.$229K
- Roche Products Limited$91K
- Boehringer Ingelheim International GmbH$4K
What the payments were for
- Consulting fees$52,97013%
- Speaking & faculty fees$300,11175%
- Travel & lodging$27,5357%
- Food & beverage$16,8624%
- Education$3150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 267 | $202,940 |
| Boehringer Ingelheim | 113 | $155,931 |
| ANI Pharmaceuticals, Inc. | 45 | $31,428 |
| Actelion Pharmaceuticals US, Inc. | 17 | $5,233 |
| Genentech, Inc. | 9 | $691 |
| Mallinckrodt Hospital Products Inc. | 5 | $296 |
| Abiomed | 2 | $243 |
| Astellas Pharma US Inc | 8 | $227 |
| Innovation Technologies Inc | 1 | $174 |
| Genentech USA, Inc. | 1 | $137 |
| Bayer | 3 | $94 |
| Amgen | 1 | $88 |
| Paragonix Technologies, Inc. | 2 | $65 |
| Boston Scientific | 2 | $53 |
| Sandoz | 1 | $42 |
| Johnson & Johnson | 3 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $36 |
| Vapotherm Inc | 1 | $24 |
| Atricure, Inc. | 1 | $20 |
| Merck | 1 | $18 |
| Livanova USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$397,794 in reported general payments places this provider in the 95th percentile of 618 critical care medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 505 | $6,397,177 |
| UptraviSelexipag | 25 | $629,021 |
| Tyvaso DpiTreprostinil | 26 | $626,338 |
| AdempasRiociguat | 46 | $605,652 |
| OpsumitMacitentan | 44 | $541,325 |
| Pirfenidone | 114 | $197,721 |
| Mycophenolate Mofetil | 203 | $89,991 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $16,717 |
| Sirolimus | 15 | $11,081 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $10,743 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $7,795 |
| Sildenafil Citrate | 51 | $7,574 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $2,333 |
| Azathioprine | 25 | $1,352 |
| Prednisone | 120 | $1,034 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $155,931 | $6,397,177505 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $5,233 | $1,170,34669 claims |
| BayerAdempas | $94 | $605,65246 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 618 critical care medicine providers in Florida.
Other critical care medicine in Tampa
- Marwan OdeeshTampa$12K
- Adam KatzTampa$9K
- Jean Kathryn GoTampa$9K
- Kevin SierraTampa$7K
- Humayun LodhiTampa$7K
- Louis GuzziOrlando$635K
- Fortune AlabiKissimmee$587K
- Fred UmehKissimmee$371K
- Amit TandonWesley Chapel$338K
- Omid ZadOrlando$325K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.